Dr. David Altarac Net Worth

The estimated Net Worth of David Altarac is at least $712 Thousand dollars as of 19 October 2021. Dr Altarac owns over 3,759 units of Entasis Therapeutics Inc stock worth over $101,268 and over the last 5 years he sold ETTX stock worth over $11,991. In addition, he makes $598,288 as Chief Medical Officer at Entasis Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr Altarac ETTX stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Entasis Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,759 units of ETTX stock worth $11,991 on 19 October 2021.

The largest trade he's ever made was selling 3,759 units of Entasis Therapeutics Inc stock on 19 October 2021 worth over $11,991. On average, Dr trades about 470 units every 0 days since 2019. As of 19 October 2021 he still owns at least 46,241 units of Entasis Therapeutics Inc stock.

You can see the complete history of Dr Altarac stock trades at the bottom of the page.

Dr. David Altarac biography

Dr. David Altarac is the Chief Medical Officer at Entasis Therapeutics Inc.

What is the salary of Dr Altarac?

As the Chief Medical Officer of Entasis Therapeutics Inc, the total compensation of Dr Altarac at Entasis Therapeutics Inc is $598,288. There are 1 executives at Entasis Therapeutics Inc getting paid more, with Dr. Manoussos Perros having the highest compensation of $934,846.

How old is Dr Altarac?

Dr Altarac is 60, he's been the Chief Medical Officer of Entasis Therapeutics Inc since . There are 1 older and 6 younger executives at Entasis Therapeutics Inc. The oldest executive at Entasis Therapeutics Holdings Inc is Dr. John Patrick Mueller Ph.D., 61, who is the Chief Devel. Officer.

What's Dr Altarac's mailing address?

David's mailing address filed with the SEC is C/O ENTASIS THERAPEUTICS HOLDINGS INC.,, 35 GATEHOUSE DRIVE, WALTHAM, MA, 02451.

Insiders trading at Entasis Therapeutics Inc

Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over $348,925 worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth $170,673,776 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Inc.Innoviva Strategic Oppo..., and Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $4,855,580. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth $42,395,047.

What does Entasis Therapeutics Inc do?

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).

Complete history of Dr Altarac stock trades at Entasis Therapeutics Inc

Entasis Therapeutics Inc executives and stock owners

Entasis Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Manoussos Perros,
  Pres, CEO & Director
• Dr. David Altarac,
  Chief Medical Officer
• Dr. John Patrick Mueller Ph.D.,
  Chief Devel. Officer
• Kristie Wagner,
  Interim VP & Interim Principal Financial and Accounting Officer
• Anna Diaz Triola MBA,
  Chief Commercial Officer
• Dr. Matthew Ronsheim Ph.D.,
  Chief Pharmaceutical Sciences & Manufacturing Officer
• Colleen Tucker,
  Head of HR
• Elizabeth M. Keiley,
  Gen. Counsel
• Dr. Ruben Tommasi,
  Chief Scientific Officer
• Dr. Michael J. Gutch MBA, Ph.D.,
  CFO, Chief Bus. Officer & Sec.
• Life Sciences Viii, L.P.Top...,
  
• Anna Diaz Triola,
  Chief Commercial Officer
• Inc. Innoviva,,
  10% owner
• Venture Partners Ix, L.P.So...,
  
• Lifesciences Iii, L.P.Claru...,
  
• Group Holdings (Sbs) Adviso...,
  
• Ruben Tommasi,
  Chief Scientific Officer
• Robin Isaacs,
  Chief Medical Officer
• Nicholas Galakatos,
  Director
• James N Topper,
  Director
• Bio Venture Partners Fund I...,
  
• Life Sciences Viii, L.P.Fhm...,
  
• Plcastrazeneca Ab Astrazeneca,
  
• Holdings A/S Novo,
  10% owner
• John Patrick Mueller,
  Chief Development Officer
• Heather Preston,
  Director
• Gregory Norden,
  Director
• David C Hastings,
  Director
• Heather A. Berger,
  Director
• Howard Mayer,
  Director
• David D. Meek,
  Director
• David Altarac,
  Chief Medical Officer
• Eric Wilson Kimble,
  Chief Commercial Officer
• Elizabeth M Keiley,
  General Counsel
• Kristie Ann Wagner,
  VP, Principal Fin & Acct Off
• Inc.Innoviva Strategic Oppo...,
  
• Manoussos Perros,
  President and CEO
• Michael Gutch,
  See Remarks
• Matthew Ronsheim,
  Chief of Pharma Sciences & MFG